Subscriber Content Preview | Request a free trialSearch  


Coming soon: Big deals, bigger busts

Finally! Boldface buyouts, blockbuster mergers and some old LBO busts on the way in 2015. Here's a look at some of the themes and headlines likely to dominate the next 12 months. Continue reading

Allergan's $66 billion Actavis deal still a win for Pershing

Valeant says it can't justify $219 a share offer to shareholders. Continue reading

Pfizer strikes immuno-oncology pact with Merck

The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards. Continue reading

Activists find help in the shadows

Companies have used private detectives for years. Now, dissident shareholders are hiring their own gumshoes. With everybody watching everybody else, at least one group wins: The investigation firms. Continue reading

Ackman launches activist campaign at Zoetis

Investors will look for response from Zoetis on its investor day scheduled for Nov. 18. Continue reading

Intercept seen as poster-boy for possible biotech bubble

The stock remains high despite concerns about an old research scandal. Continue reading

The Untouchables: Where insurgents fear to tread

Up to now, companies in highly regulated industries were safe from activists. That may be changing in this era of de-regulation, with some of the checks on activists that existed a couple of decades ago falling away. Continue reading

Third Point tells Amgen: Break it up

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting. Continue reading

AbbVie backs away from Shire takeover after tax changes

The Dublin target insists the deal should go ahead and notes that it's in line for a $1.635 billion breakup fee if it collapses. Continue reading

Rural Metro award could have far-reaching effects

The $76M judgment was one of the largest in the history of the Court of Chancery. Continue reading

Working on the A[ctivist]-Team

Dissidents find teaming up helps cover costs and drive insurgencies at larger companies. But the members of the group must stay on the same page and share the same goals if a target agrees to sell itself. Continue reading

Steris chases tax cuts with Synergy Health purchase

The Ohio company defies a regulatory clampdown on inversions with the $1.9 billion deal. Continue reading

Meet the journalists

Jim Cramer's 2013 M&A predictions

The Founder of and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!